BioSpace News Archive

Funds will support preclinical verification studies of its Total Artificial Heart in preparation for first in human early feasibility studies.

Focus on Computational Health Merges Strengths in Artificial Intelligence and Machine Learning with Biological and Biomedical Expertise to Launch Companies That Revolutionize Diagnostic and Therapeutic Outcomes

Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, announced that Lawrence Blatt, Ph.D., MBA, CEO of Aligos, will present at the Jefferies Virtual Healthcare Conference being held June 1- 4, 2021.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board of Directors.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the following investor conferences. William Blair 41 st Annual Growth Stock Conference Fireside Chat on Tuesday, June 1 st at 6:40 a.m. Pacific Time / 9:40 a.m. Eastern Time

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Anne-Virginie Eggimann, M.Sc., to its board of directors.

IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies, announced today that topline data from the first cohort of the on-going INB-200 Phase 1 clinical study of DeltEx Drug Resistant Immunotherapy, or DeltEx DRI, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting as part of a poster discussion session.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS ™ (voclosporin) in Subjects with Lupus Nephritis - Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with no change in mean eGFR at 104 weeks of treatment -

American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three months ended March 31, 2021. Chief Executive Officer Melissa A. Waterhouse stated, “As I indicated in April 2021, sales of Covid-19 tests have declined significantly from previous levels.